Chemist Body Seeks Transition Period, GST Input Adjustment After Tax Cut, Writes to CM
- byDoctor News Daily Team
- 09 September, 2025
- 0 Comments
- 0 Mins

New Delhi:The Retail Distribution Chemist Alliance (RDCA) has written to the Delhi government, seeking urgent relief measures to manage the impact of the recent Goods and Services Tax (GST) reduction on medicines from 12% to 5%, effective September 22, 2025. In a representation dated September 06, 2025, addressed to Delhi Chief Minister Rekha Gupta and Finance Minister, RDCA welcomed the GST reduction as a “positive step for patients” but flagged serious concerns for the trade. “The reduction of GST on medicines from 12% to 5% w.e.f. 22nd September 2025 is a welcome step for patients. However, it has created heavy accumulation of GST inputs and unsold higher-cost stock with pharmacies, causing immediate financial stress,” the RDCA wrote. Two Key Demands from Chemists To ensure uninterrupted supply of medicines during this transition, the association proposed two specific interventions: Transition Period: A 3-month window to allow depletion of old MRP stock purchased at higher tax. Input Adjustment Mechanism: A clear framework within 6 months for adjusting accumulated GST inputs to prevent losses for small and mid-sized pharmacies. “These timely relief measures will protect the pharma trade and ensure uninterrupted patient care in Delhi,” the letter emphasised. Representation from RDCA The representation was submitted by RDCA President Sandeep Nangia, who is also Organising Secretary of the All India Organisation of Chemists and Druggists (AIOCD). A copy of the letter has also been sent to AIOCD’s Mumbai headquarters. RDCA represents a large network of retail chemists in the capital. By escalating the matter to AIOCD, the national body of chemists, the association has highlighted that the issue is not limited to Delhi but could impact medicine supply chains across India if left unaddressed. The GST reduction follows a decision by the GST Council to lower tax on 33 lifesaving drugs, including cancer medicines, to make essential treatments more affordable for patients. While patients are expected to benefit from lower prices, traders argue that the sudden shift without a transition mechanism places financial strain on pharmacies holding higher-tax inventory. As of now, the Delhi government has not issued any response to RDCA’s demands.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Recent News
OTC Access to Oral Contraceptives May Improve Equi...
- 18 September, 2025
Leading cancer societies update clinical guideline...
- 18 September, 2025
Early SSRF Reduces Mortality and Improves Outcomes...
- 18 September, 2025
PFO effectively alleviates pain and enhances joint...
- 18 September, 2025
Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!